The Effect of a Twice Daily, 200 mg Dose of Oral Fidaxomicin Compared to Placebo on Risk of Acquiring C. Difficile and Developing C. Difficile Infection (CDI) in High Risk Patients

Trial Profile

The Effect of a Twice Daily, 200 mg Dose of Oral Fidaxomicin Compared to Placebo on Risk of Acquiring C. Difficile and Developing C. Difficile Infection (CDI) in High Risk Patients

Withdrawn prior to enrolment
Phase of Trial: Phase IV

Latest Information Update: 27 May 2014

At a glance

  • Drugs Fidaxomicin (Primary)
  • Indications Clostridium infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 19 Jul 2012 Planned initiation date changed from 1 Apr 2012 to 1 Sep 2012 as reported by ClinicalTrials.gov.
    • 21 Mar 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top